Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
INVO Fertility ( (IVF) ) just unveiled an announcement.
On August 21, 2025, INVO Fertility, Inc. and Five Narrow Lane LP amended their financial agreement, reducing the principal amount of a debenture and exchanging it for preferred stock shares. Additionally, they extended deadlines for filing and effectiveness of a registration statement with the SEC, impacting the company’s financial operations and stakeholder interests.
The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Underperform.
The overall stock score is primarily impacted by poor financial performance and bearish technical indicators. The company’s significant operational losses and high leverage pose substantial risks. The negative P/E ratio and lack of dividend yield further weaken the valuation. Despite a positive corporate event, the overall outlook remains challenging.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. operates in the fertility industry, focusing on providing innovative fertility treatment solutions. The company is known for its INVOcell technology, which offers a more natural and affordable option for assisted reproductive procedures.
Average Trading Volume: 1,516,348
Technical Sentiment Signal: Sell
Current Market Cap: $4.8M
See more insights into IVF stock on TipRanks’ Stock Analysis page.